Additionally, treatment with G6PD AG1 activator (a selective G6PD activator) significantly increased G6PD activities and reduced γ-H2AX and 53BP1 expression, while DADS treatment reversely reduced G6PD activities and partially rescued γ-H2AX and 53BP1 expression in CRC cells (P<0.05, Figure S3E-F). The gene discussed is G6PD; the disease is colorectal carcinoma.